Business
PharmaCyte Biotech Appoints Dr. José Iglesias as Consulting Chief Medical Officer for Clinical Trial in Pancreatic Cancer
LAGUNA HILLS, Calif.--(BUSINESS WIRE)-- PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing targeted cellular therapies for
About this update from Pharmacyte Biotech, Inc.
[{"type":"text","content":" LAGUNA HILLS, Calif.--(BUSINESS WIRE)--\nPharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that it has appointed José L. Iglesias M.D. as Consulting Chief Medical Officer (CMO) for its planned Phase 2b clinical trial in locally advanced, inoperable pancreatic cancer (LAPC).\n\n\nDr. Iglesias brings a wealth of experience in developing and testing a variety of cancer chemotherapeutic agents to PharmaCyte, including key positions with many prominent biotechnology firms including Eli Lilly, Amgen, Abraxis and Celgene. Dr. Iglesias’s body of work is ideally suited to guide PharmaCyte through its planned Phase 2b clinical trial in LAPC. As the global Vice-President of Clinical Development at Celgene, Dr. Iglesias was the lead physician on the team that obtained FDA approval for Abraxane® (the nab-paclitaxel/gemcitabine combination), which is a first-line therapy in pancreatic cancer.\n\n\nDr. Iglesias is also familiar and experienced with the treatment of various abdominal cancers and the use of gemcitabine in patients. He was instrumental in the design of the Phase 3 clinical trial for the development of nab-paclitaxel for use against metastatic pancreatic cancer while at Celgene.\n\n\nPharmaCyte’s Chief Executive Officer, Kenneth L. Waggoner, stated, “We are extremely fortunate to have Dr. Iglesias join PharmaCyte for our planned Phase 2b clinical trial in LAPC. We interviewed a number of impressive candidates, but his experience in dealing with various cancer chemotherapeutic agents and, more importantly, his direct knowledge in treating pancreatic cancer make him the obvious choice for the position of Consulting CMO for our clinical trial.\n\n\nI would be remiss in not saying that Dr. Manuel Hidalgo, who will be the Principal Investigator for our planned clinical trial in LAPC, personally recommended Dr. Iglesias to us for consideration. Dr. Hidalgo considers Dr. Iglesias to be one of the most brilliant physicians in the field.”\n\n\nDr. Iglesias has been awarded numerous prestigious fellowships, and he is the co-author of 68 publications in scientific journals.\n\n\nTo learn more about PharmaCyte’s pancreatic cancer treatment and how it works inside the b...